Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Upgraded by StockNews.com

Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.

Other equities research analysts have also recently issued research reports about the company. Piper Sandler increased their price target on Amphastar Pharmaceuticals from $66.00 to $71.00 in a report on Wednesday, August 9th. Jefferies Financial Group began coverage on Amphastar Pharmaceuticals in a report on Tuesday, July 25th. They set a “buy” rating and a $70.00 price target on the stock.

Amphastar Pharmaceuticals Stock Up 5.2 %

NASDAQ AMPH opened at $56.31 on Monday. Amphastar Pharmaceuticals has a one year low of $27.58 and a one year high of $67.66. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.68 and a current ratio of 2.11. The business has a fifty day moving average price of $47.08 and a 200 day moving average price of $50.25. The company has a market cap of $2.70 billion, a P/E ratio of 22.00 and a beta of 0.87.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 2,000 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, August 18th. The stock was sold at an average price of $52.50, for a total value of $105,000.00. Following the sale, the director now owns 40,895 shares in the company, valued at $2,146,987.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Yakob Liawatidewi sold 28,816 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $53.13, for a total value of $1,530,994.08. Following the completion of the sale, the executive vice president now owns 69,669 shares in the company, valued at approximately $3,701,513.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 2,000 shares of the company’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $52.50, for a total value of $105,000.00. Following the transaction, the director now owns 40,895 shares in the company, valued at $2,146,987.50. The disclosure for this sale can be found here. Insiders sold 92,559 shares of company stock worth $4,824,984 in the last 90 days. Insiders own 27.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. West Tower Group LLC acquired a new position in shares of Amphastar Pharmaceuticals in the second quarter worth $39,000. Pacer Advisors Inc. purchased a new position in Amphastar Pharmaceuticals in the second quarter valued at $59,000. Ronald Blue Trust Inc. increased its holdings in Amphastar Pharmaceuticals by 821.5% during the 3rd quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock worth $55,000 after purchasing an additional 1,068 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Amphastar Pharmaceuticals by 99.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock worth $58,000 after purchasing an additional 628 shares during the period. Finally, Point72 Middle East FZE acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter valued at about $50,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).